Experimental immune cell therapy for liver cancer hits early roadblock
Disease control
Terminated
This early-stage trial tested a new type of immune cell therapy (ET140203 T cells) in 8 adults with advanced liver cancer that had not responded to other treatments. The therapy was designed to target a protein called AFP found on cancer cells. The study was terminated early, so …
Phase: PHASE1 • Sponsor: Eureka Therapeutics Inc. • Aim: Disease control
Last updated Jun 26, 2026 15:13 UTC